OPRM1 A118G SNP, Alcohol Response, and Striatal Dopamine
NCT00401999 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35
Last updated 2017-07-02
Summary
This study will examine the relationship between variations in a gene called OPRM1 and the response to alcohol. The OPRM1 (Mu-opioid Receptor-1) gene helps regulate brain pathways involved in experiencing pleasure. Brain pathways use a chemical called dopamine. Different forms of the OPRM1 gene may lead to differences in how dopamine is released and subsequently to differences in a person's response to alcohol.
Healthy non-smokers between 21 and 45 years of age may be eligible for this study. Candidates are screened with a medical and psychiatric history and physical examination, blood and urine tests, and breathalyzer (breath alcohol test). A blood test is also done to determine the variant of OPRM1 gene.
Participants undergo the following procedures in three study sessions:
Session 1
" Breathalyzer test, urine test for illicit drugs and pregnancy test for women who can become pregnant.
" Insertion of catheters (plastic tubes) into a vein in one arm for infusing alcohol and into the other arm for drawing blood samples.
" Completion of questionnaires on how intoxicated the subject feels.
" Blood draw for research studies.
" Eye movement test (a visor with a digital camera tracks the subject's eye movements while he or she watches lights on a computer screen).
" 45-minute alcohol infusion (up to 0,08 grams per deciliter - a level considered in most states as driving under the influence of alcohol).
" Repeat breathalyzer, questionnaires, eye movement test and blood draw every 15 minutes during the infusion and again after the infusion is complete.
" Subjects remain in the clinic until their blood alcohol content falls below 0.02 g/dL, determined by a breathalyzer test done every 15 minutes. Subjects can usually return home about 3 to 4 hours after the alcohol infusion stops.
Sessions 2 and 3
The procedure is the same as for session 1, except subjects receive an infusion of alcohol one session and an infusion of saline (salt water) the other. Also, subjects undergo positron emission tomography (PET) scanning during the infusions. For this test, the subject lies on a bed that slides in and out of a doughnut-shaped scanner. A custom-molded mask is used to support the head and prevent it from moving during the scanning. A small amount of radioactive substance called C-11 raclopride is injected through one of the catheters to trace brain dopamine activity.
...
Conditions
- Alcoholism
Sponsors & Collaborators
-
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
lead NIH
Eligibility
- Min Age
- 21 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-11-16
- Completion
- 2011-01-28
Countries
- United States
Study Locations
More Related Trials
-
Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism
NCT00920829 ·Status: COMPLETED ·Phase: PHASE4
-
Involvement of the Septal Nuclei of the Human Brain in Alcohol Use Disorder
NCT06866379 ·Status: RECRUITING ·Phase: NA
-
Endophenotype for Alcohol Misuse in Healthy Minority Populations
NCT00256451 ·Status: COMPLETED ·Phase: PHASE4
-
Characterization Imaging Instruments in Alcoholics and Non-Alcoholics
NCT02108080 ·Status: RECRUITING
-
Exploring Regulation and Function of Dopamine D3 Receptors in Alcohol Use Disorders: A [11C]-(+)-PHNO Study
NCT03037060 ·Status: COMPLETED ·Phase: NA
-
Neurobiology of Alcohol and Nicotine Co-Addiction
NCT03338933 ·Status: COMPLETED
-
Cerebellar Involvement in Alcohol Use Disorder (AUD)
NCT05732207 ·Status: RECRUITING ·Phase: NA
-
Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.
NCT00366626 ·Status: COMPLETED ·Phase: PHASE4
-
[C-11]NOP-1A and Alcohol Use Disorder
NCT03448016 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice
NCT06312657 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Effects of GSK598809 on Brain Activation in Abstinent Alcoholics
NCT00908206 ·Status: WITHDRAWN ·Phase: PHASE1
-
Multisensory Processing of Alcohol Cues in Young Adult Binge Drinkers
NCT06885190 ·Status: NOT_YET_RECRUITING
-
Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant
NCT05203965 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
EtOH Interaction Study
NCT00887367 ·Status: COMPLETED ·Phase: PHASE1
-
INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers
NCT02989662 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion
NCT00667771 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
NCT03745339 ·Status: RECRUITING
-
Naltrexone for Individuals of East Asian Descent
NCT02026011 ·Status: COMPLETED ·Phase: PHASE2
-
A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel
NCT01531920 ·Status: COMPLETED ·Phase: PHASE1
-
Alcohol, Behavior, and Brain Imaging
NCT03930446 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control
NCT02949934 ·Status: COMPLETED ·Phase: PHASE2
-
Neuroimmune Dysfunction in Alcohol Use Disorder
NCT04210713 ·Status: COMPLETED ·Phase: PHASE1
-
Targeted Extinction of Drug Cues During Sleep - Olfactory Cue Reactivity Task
NCT05189379 ·Status: COMPLETED ·Phase: NA
-
Ketamine/Placebo Family History Positive Study
NCT00588952 ·Status: COMPLETED ·Phase: NA
-
Family History Study of Alcohol Consumption Using Memantine
NCT00630955 ·Status: COMPLETED ·Phase: PHASE2